Luigi Grasso
Gründer bei Navrogen, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Nicholas C. Nicolaides | M | 58 |
Navrogen, Inc.
 Navrogen, Inc. Pharmaceuticals: MajorHealth Technology Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA.
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | 24 Jahre |
| Steven Kyriakos | M | - |
Navrogen, Inc.
Navrogen, Inc. Pharmaceuticals: MajorHealth Technology Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA. | 6 Jahre |
| Rodney Dausch | M | - |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | 22 Jahre |
| Lonnie Moulder | M | 66 |
Navrogen, Inc.
Navrogen, Inc. Pharmaceuticals: MajorHealth Technology Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA. | - |
| Enrico Denise Petrillo | M | 68 |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | 23 Jahre |
| Joye L. Bramble | M | - |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | 14 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Philip M. Sass | M | - |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | - |
| William D. Claypool | M | 72 |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | 2 Jahre |
| David K. Stone | M | 67 |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | - |
| John H. Kim | M | - |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 10 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Luigi Grasso
- Persönliches Netzwerk